Trial
NCT01186406
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Duke University
Collaborators
Genentech, Inc.; Eisai Inc.
Condition
Glioblastoma Multiforme
Intervention
Gliadel
Why stopped
Study ended early due to toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-02-15